US FDA gives Geron's stem cell trial the green light, again
This article was originally published in Scrip
Executive Summary
The US FDA has lifted a clinical hold and given Geron the green light to push its stem cell-derived therapy GRNOPC1 into what could be the first trial in the US of embryonic stem cells. The move, which meets with a previously announced timeline for when the hold would be removed, sent Geron's share price up by 17% on 30 July, to $5.63 on Nasdaq.